Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 16/20 | 0.72 |
| ▸ | CYP11B1 | P15538 | 15/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.68 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.61 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26260191 | 0.84 | CYP11B2 (0.52) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12051687 | 0.84 | HSD17B1 (0.83) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL11723032 | 0.84 | HSD17B1 (0.83) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3004402 | 0.84 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL28300293 | 0.82 | ESR2 (0.52) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12027311 | 0.81 | CYP11B2 (0.76) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4500403 | 0.81 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23249746 | 0.80 | FTO (0.71) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL22106285 | 0.80 | HSD17B1 (0.76) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3020390 | 0.80 | HSD17B1 (0.76) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221591-A1 | Selective Inhibitors of Human Corticosteroid Synthases | UNIVERSITAT DES SAARLANDES (DE) | 2009-09-03 | — | — | US | claimed |
| EP-4748838-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12630527-B2 | Broad spectrum anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4045498-B1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | UNIV CALIFORNIA (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| EP-4045498-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | The Regents of the University of California (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076617-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076617-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| EP-1853261-B1 | SELECTIVE INHIBITORS OF HUMAN CORTICOSTEROID SYNTHASES | UNIV SAARLAND (DE) | 2017-01-11 | — | — | EP | disclosed |
| US-9271963-B2 | Selective inhibitors of human corticosteroid synthases | UNIVERSITAT DES SAARLANDES (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20090221591-A1 | Selective Inhibitors of Human Corticosteroid Synthases | UNIVERSITAT DES SAARLANDES (DE) | 2009-09-03 | — | — | US | disclosed |
| EP-1853261-A1 | SELECTIVE INHIBITORS OF HUMAN CORTICOSTEROID SYNTHASES | Universität des Saarlandes (DE) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006092430-A1 | SELECTIVE INHIBITORS OF HUMAN CORTICOSTEROID SYNTHASES | Universität des Saarlandes (DE) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221591-A1 | Selective Inhibitors of Human Corticosteroid Synthases | CYP11B1, HSD11B1, HSD17B1 | CYP11B2 5/4885CYP11B1 1/4885CYP1A2 38/4885 |
| US-12630527-B2 | Broad spectrum anti-cancer compounds | YTHDF3, YTHDF1, YTHDF2 | CYP11B2 4725/4885CYP11B1 4576/4885CYP1A2 4783/4885 |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | YTHDF1, YTHDF3, YTHDF2 | CYP11B2 4798/4885CYP11B1 4704/4885CYP1A2 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.